Assessing Bladder Cancer Risk in Type 2 Diabetes Clinical Trials: the Dapagliflozin Drug Development Program as a ‘Case Study’

Por Ptaszynska, Agata, Cohen, Samuel M., Messing, Edward M., Reilly, Timothy P., Johnsson, Eva, Johnsson, Kristina
Publicado no Diabetes Ther (2015)

Targeting the kidney and glucose excretion with dapagliflozin: preclinical and clinical evidence for SGLT2 inhibition as a new option for treatment of type 2 diabetes mellitus

Por Whaley, Jean M, Tirmenstein, Mark, Reilly, Timothy P, Poucher, Simon M, Saye, JoAnne, Parikh, Shamik, List, James F
Publicado em 2012

Mice Lacking Natural Killer T Cells Are More Susceptible to Metabolic Alterations following High Fat Diet Feeding

Por Martin-Murphy, Brittany V., You, Qiang, Wang, Hong, De La Houssaye, Becky A., Reilly, Timothy P., Friedman, Jacob E., Ju, Cynthia
Publicado em 2014

Carcinogenicity Risk Assessment Supports the Chronic Safety of Dapagliflozin, an Inhibitor of Sodium–Glucose Co-Transporter 2, in the Treatment of Type 2 Diabetes Mellitus

Por Reilly, Timothy P., Graziano, Michael J., Janovitz, Evan B., Dorr, Thomas E., Fairchild, Craig, Lee, Francis, Chen, Jian, Wong, Tai, Whaley, Jean M., Tirmenstein, Mark
Publicado em 2014